Industry
Biotechnology
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
June 04, 2024 | 12:13 pm
Portfolio Pulse from Benzinga Newsdesk
May 22, 2024 | 12:14 pm
Portfolio Pulse from Benzinga Insights
April 24, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Newsdesk
April 18, 2024 | 12:09 pm
Portfolio Pulse from Benzinga Insights
April 15, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Insights
April 01, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
March 11, 2024 | 12:02 pm
Portfolio Pulse from Benzinga Insights
March 04, 2024 | 5:34 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.